Pharmacogenomics, ancestry and clinical decision making for global populations

Pharmacogenomics Journal

Volumn 14, Issue 3, 2014, Pages 217-222

  Ramos, E ^a   Doumatey, A ^a   Elkahloun, A G ^a   Shriner, D ^a   Huang, H ^a   Chen, G ^a   Zhou, J ^a   McLeod, H ^b   Adeyemo, A ^a   Rotimi, C N ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

ADME; clinical decision making; global populations; pharmacogenomics

Indexed keywords

CAPECITABINE; WARFARIN;

ALLELE; ANCESTOR; ARTICLE; ASIAN; BLACK PERSON; CLINICAL DECISION MAKING; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FAMILY HISTORY; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; PHARMACOGENOMICS; POPULATION STRUCTURE; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; CLINICAL PRACTICE; PHARMACOGENETICS; POPULATION GROUP;

GENE FREQUENCY; HUMANS; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION GROUPS;

EID: 84901266701     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.24     Document Type: Article

References (30)

1. Table of pharmacogenomic biomarkers in drug labels http://www.fda.gov/ drugs/ scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
2. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144-1153.
3. Schwab M, Schaeffeler E. Pharmacogenomics: a key component of personalized therapy. Genome Med 2012; 4: 93.
4. Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr Opin Mol Therapeut 2009; 11: 260-268.
5. VeraCode ADME core panel. http://res.illumina.com/documents/products/ datasheets/datasheet-veracode-adme-core-panel.pdf.
6. Rotimi CN, Dunston GM, Berg K, Akinsete O, Amoah A, Owusu S et al. In search of susceptibility genes for type 2 diabetes in West Africa: the design and results of the first phase of the AADM study. Ann Epidemiol 2001; 11: 51-58.
7. Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, Huang H et al. A genomewide association study of hypertension and blood pressure in African Americans. PLoS Genet 2009; 5: e1000564.
8. Shriner D. Investigating population stratification and admixture using eigenanalysis of dense genotypes. Heredity (Edinb) 2011; 107: 413-420.
9. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet 2011; 20: 528-540.
10. Wang C, Szpiech ZA, Degnan JH, Jakobsson M, Pemberton TJ, Hardy JA et al. Comparing spatial maps of human population-genetic variation using Procrustes analysis. Stat Appl Genet Mol Biol 2010; 9: Article 13.
11. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008; 28: 1084-1097.
12. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
13. 1000 Genomes Project Consortium et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
14. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A et al. The genetic structure and history of Africans and African Americans. Science (New York, NY) 2009; 324: 1035-1044.
15. Shriner D. Improved eigenanalysis of discrete subpopulations and admixture using the minimum average partial test. Human Heredity 2012; 73: 73-83.
16. Clayton DG, Walker NM, Smyth DJ, Pask R, Cooper JD, Maier LM et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet 2005; 37: 1243-1246.
17. Rosenberg NA, Huang L, Jewett EM, Szpiech ZA, Jankovic I, Boehnke M. Genome-wide association studies in diverse populations. Nat Rev Genet 2010; 11: 356-366.
18. Larussa T, Suraci E, Lentini M, Nazionale I, Gallo L, Abenavoli L et al. High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease. Eur J Intern Med 2012; 23: 273-277.
19. Dai Z, Papp AC, Wang D, Hampel H, Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 2008; 1: 24.
20. Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 2011; 12: 13.
21. Tegretol Drug Label http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/ 016608s107,018281s055,018927s048,020234s040lbl.pdf.
22. Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn 2009; 11: 216-225.
23. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010; 55: 582-589.
24. Sung C, Lee PL, Tan LL, Toh DS. Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority. Drug Saf 2011; 34: 1167-1175.
25. Bhatia G, Patterson N, Pasaniuc B, Zaitlen N, Genovese G, Pollack S et al. Genomewide comparison of African-ancestry populations from CARe and other cohorts reveals signals of natural selection. Am J Human Genet 2011; 89: 368-381.
26. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011; 90: 625-629.
27. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med 2010; 363: 1551-1558.
28. Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J 2011; 11: 100-107.
29. He YJ, Shapero MH, McLeod HL. Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. Pharmacogenet Genomics 2012; 22: 322-324.
30. Ramos E, Callier SL, Rotimi CN. Why personalized medicine will fail if we stay the course. Personalized Med 2012; 9: 839-847.